Home Biosimilar Antibodies Immunology & Inflammation Interleukins Secukinumab (anti-IL-17A)
For research use only. Not for use in humans.

Secukinumab (anti-IL-17A)

Synonyms: IL-17A,Ctl

Secukinumab (anti-IL-17A) (AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa.

Secukinumab (anti-IL-17A)

Click to purchase the isotype control of Secukinumab (anti-IL-17A)

4 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A202501 Purity: 99.82% Protein concentration: 5.00mg/ml Endotoxin Level: <1EU/mg
99.82

Specificity

Name Citation IL-6 IL-1 IL-8 IL-12 IL-10 IL-13 IL-2 Others
SKF-86002 1
JTE-607 Dihydrochloride 2 TNF-alpha
A-740003 2 rat P2X7 receptor,human P2X7 receptor
Apilimod mesylate 6 PIKfyve
MD2-TLR4-IN-1 2 TLR4,TNF-α
Danirixin (GSK1325756) 2 CXCR2
Resatorvid (TAK-242) 65 TLR4,NO,TNF-α
Apilimod (STA-5326) 19 PIKfyve
LMT-28 1
Atractylodin 0 NAAA
Triolein 0 ROS,MMP-1
Ac-YVAD-cmk 5
Diethyl phosphate 1
RCM-1 5 STAT6,FOXM1,β-catenin
Stylopine 0 COX-2,TNF-α,NO
Myrislignan 1 NF-κB,COX-2,iNOS
NE 52-QQ57 2 iNOS,TNF-α,PGE2
PKR-IN-C16 9 PKR
(3R,8S)-Falcarindiol 3 STAT,ERK,JNK
Gardenoside 1 P2X7 Receptor,P2X3 receptor,NF-κB
T-5224 23 c-Jun,c-Fos/AP-1,Adamts-5
IQ 3 1 TNF-α,JNK3,JNK1
Isuzinaxib (APX-115 free base) 2 TNFα,MCP-1/CCL2,NOX2
AUDA 1 p38,Smad3,TGF-β
SAR-20347 1 IFN-α,TYK2,JAK1
SU 5201 0
Madecassic acid 3 TNF-α,COX-2,iNOS
Homoplantaginin 1 NF-κB,IKKβ,TNF-α
2',5'-Dihydroxyacetophenone 1 NF-κB,ERK1/2,iNOS
Forsythoside B 0 NF-κB,TNF-alpha,IκB
Mulberroside A 0 NF-κB,Caspase-1,NALP3
Chelidonic acid 0 glutamate decarboxylase,Caspase-1,NF-κB
4-Methylesculetin 2 MPO
Muscone 4 TNF-α,NLRP3 inflammasome,NF-κB
Ossirene (AS101) 16
Methylthiouracil 1 ERK1/2,NF-κB,TNF-α
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Secukinumab (anti-IL-17A) (AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa.
In vitro

Secukinumab can reduce cell growth in the miR130b-knockdown OCI-ly10 co-culture system.
Cell Research

MTT assay was adopted to measure cell growth in the control inhibitor or miR130b inhibitor transfected OCI-ly10 co-culture system upon treatment with or without IL17 inhibitor.
In vivo

Secukinumab administration significantly attenuates AAV8-IRF8 mediated recruitment of neutrophils, also downregulates the autophagy level and inhibits the release of either autophagy-dependent or independent chemokines in vivo.
Animal Research

Animal Models: C57BL/6 mice, IRF8 FLOX mice (C57BL/6J background)
Dosages: 200 μg
Administration: i.p.
Reference: https://pubmed.ncbi.nlm.nih.gov/34400126/
 
References

Product Details

CAS No. 1229022-83-6
Isotype Human IgG1
Source Human
Sterility 0.2 μM filtered
Formulation PBS buffer, pH 7.2
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07352566 NOT_YET_RECRUITING Drug: Triamcinolone|Drug: 5-Fluorouracil|Drug: Calcipotriene Psoriasis; Atopic Dermatitis University of California, San Francisco 2026-08-01 PHASE4
NCT04638647 RECRUITING Autoimmunity, Inflammation Novartis Pharmaceuticals 2020-12-22 PHASE4
NCT06751238 RECRUITING Juvenile Psoriatic Arthritis Novartis Pharmaceuticals 2025-09-24 PHASE1
NCT07477795 NOT_YET_RECRUITING Drug: Secukinumab Takayasu Arteritis; Large Vessel Vasculitis Assistance Publique - Hôpitaux de Paris 2026-04-01 PHASE2
NCT07489573 RECRUITING Drug: Secukinumab Hidradenitis Suppurativa (HS) Novartis Pharmaceuticals 2026-06-01 PHASE4
NCT07704190 NOT_YET_RECRUITING Cardiorenal Metabolic Syndrome; Atherosclerotic Cardiovascular Disease; Chronic Kidney Disease; Coronary Artery Disease; Hypertension; Type 2 Diabetes Mellitus; Peripheral Arterial Disease; Carotid Artery Stenosis Peking University Third Hospital 2026-07-15 PHASE4

(data from https://clinicaltrials.gov, updated on 2026-06-03)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.